MoonLake Immunotherapeutics (MLTX) Tax Provisions (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Tax Provisions of $622000.0 for Q1 2026, up 306.54% year-over-year from $153000.0 in Q1 2025, and up 150.81% quarter-over-quarter from $248000.0 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Tax Provisions (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Tax Provisions history runs 6 years deep, the most recent figure standing at $622000.0 for Q1 2026.
- In Q1 2026, Tax Provisions rose 306.54% year-over-year to $622000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 195.89% YoY), while the FY2025 annual figure was $611000.0, up 116.67% from the prior year.
- Tax Provisions for Q1 2026 stood at $622000.0, up from $248000.0 in the prior quarter.
- The five-year high for Tax Provisions was $622000.0 in Q1 2026, with the low at $7332.0 in Q1 2022.
- The 5-year median for Tax Provisions is $43920.0 (2023), against an average of $96786.4.
- Peak annual rise in Tax Provisions reached 678.4% in 2024, while the deepest fall reached 6.65% in 2024.
- MoonLake Immunotherapeutics' Tax Provisions stood at $11012.0 in 2022, then surged by 298.84% to $43920.0 in 2023, then declined by 6.65% to $41000.0 in 2024, then jumped by 504.88% to $248000.0 in 2025, then surged by 150.81% to $622000.0 in 2026.
- Business Quant data shows MLTX's Tax Provisions at $622000.0 in Q1 2026, $248000.0 in Q4 2025, and $115000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 90,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90,000.00 |
| Mar 31, 2026 | 622,000.00 |
| Dec 31, 2025 | 248,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Mar 31, 2025 | 153,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 43,920.00 |
| Sep 30, 2023 | 28,923.00 |
| Jun 30, 2023 | 10,149.00 |
| Mar 31, 2023 | 11,010.00 |
| Dec 31, 2022 | 11,012.00 |
| Sep 30, 2022 | 8,740.00 |
| Jun 30, 2022 | 9,282.00 |
| Mar 31, 2022 | 7,332.00 |
| Dec 31, 2021 | 4,755.00 |